Isoniazid preventive therapy: do the risks outweigh the benefits in pregnant women with HIV?

Post Date: 
. . . Isoniazid preventive therapy (IPT) during and after pregnancy in women living with HIV on antiretroviral therapy (ART) in tuberculosis (TB) endemic areas in Africa, Asia and Haiti resulted in serious adverse events quite possibly attributable to isoniazid with no significant reduction in TB cases, participants heard last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2018) in Boston.
Adverse pregnancy outcomes were significantly higher among women getting IPT during pregnancy than after (23% (106) and 17% (77), respectively, p = .009), Dr Amita Gupta presenting on behalf of the IMPAACT P1078/TB Apprise study team stated . . .